Published in Proc Natl Acad Sci U S A on June 01, 1977
H-2Dd exploits a four residue peptide binding motif. J Exp Med (1993) 1.13
Modelling of the combining sites of three anti-lysozyme monoclonal antibodies and of the complex between one of the antibodies and its epitope. EMBO J (1986) 0.99
Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure. Nucleic Acids Res (2012) 0.99
A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response. J Virol (1995) 0.93
Antibodies designed as effective cancer vaccines. MAbs (2010) 0.81
Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex. Protein Sci (2003) 0.80
Patterns of interallelic divergence at the rabbit b-locus of the immunoglobulin light chain constant region are in agreement with population genetical evidence for overdominant selection. Genetics (1992) 0.80
Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery. Immunol Rev (2016) 0.78
Amino acid difference formula to help explain protein evolution. Science (1974) 15.19
An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med (1970) 9.83
The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. Proc Natl Acad Sci U S A (1974) 3.92
Three-dimensional structure of the Fab' fragment of a human immunoglobulin at 2,8-A resolution. Proc Natl Acad Sci U S A (1973) 3.14
Three-dimensional structure of immunoglobulins. Annu Rev Biochem (1975) 1.99
The three dimensional structure of a combining region-ligand complex of immunoglobulin NEW at 3.5-A resolution. Proc Natl Acad Sci U S A (1974) 1.97
Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains. Ann N Y Acad Sci (1971) 1.84
Crystal and molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI. Eur J Biochem (1974) 1.76
Structural basis for the specificity of phosphorylcholine-binding immunoglobulins. Immunochemistry (1976) 1.63
Variable region sequences of five human immunoglobulin heavy chains of the VH3 subgroup: definitive identification of four heavy chain hypervariable regions. Proc Natl Acad Sci U S A (1974) 1.52
Relations between chemical structure and biological activity in peptides. J Theor Biol (1966) 1.51
Binding of 2,4-dinitrophenyl compounds and other small molecules to a crystalline lambda-type Bence-Jones dimer. Biochemistry (1974) 1.15
Variability of three-dimensional structure in immunoglobulins. Proc Natl Acad Sci U S A (1975) 1.09
Amino-acid sequence of an allotype b4 light chain from a rabbit antibody to streptococcal carbohydrate. Proc Natl Acad Sci U S A (1974) 1.07
Attempts to locate residues in complementarity-determining regions of antibody combining sites that make contact with antigen. Proc Natl Acad Sci U S A (1976) 1.02
Different degrees of interspecies homology in immunoglobulin lamda chain constant domain correlated with three-dimensional structure. Nature (1975) 0.86
Evolutionary and structural influences on light chain constant (CL) region of human and mouse immunoglobulins. Proc Natl Acad Sci U S A (1975) 0.86
Diversity of light chain variable region sequences among rabbit antibodies elicited by the same antigens. Proc Natl Acad Sci U S A (1975) 0.85
Some correlations between specificity and sequence of the first complementarity-determining segments of human kappa light chains. Proc Natl Acad Sci U S A (1976) 0.80
Conformations of immunoglobulin hypervariable regions. Nature (1990) 5.31
Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol (1986) 4.16
The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. Proc Natl Acad Sci U S A (1974) 3.92
Antibody-antigen complexes. Annu Rev Biochem (1990) 3.91
Three-dimensional structure of the tryptophan synthase alpha 2 beta 2 multienzyme complex from Salmonella typhimurium. J Biol Chem (1988) 3.52
Three-dimensional structure of an antibody-antigen complex. Proc Natl Acad Sci U S A (1987) 3.48
Three-dimensional structure of immunoglobulins. Annu Rev Biochem (1975) 1.99
Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proc Natl Acad Sci U S A (1987) 1.82
Antibody-antigen complexes. J Biol Chem (1988) 1.69
Structural basis for the specificity of phosphorylcholine-binding immunoglobulins. Immunochemistry (1976) 1.63
Structure at 4.5 A resolution of a phosphorylcholine-binding fab. Nat New Biol (1973) 1.60
Model-building studies of antigen-binding sites: the hapten-binding site of mopc-315. Cold Spring Harb Symp Quant Biol (1977) 1.54
Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex. J Exp Med (1992) 1.43
Structure and refinement at 1.8 A resolution of the aspartic proteinase from Rhizopus chinensis. J Mol Biol (1987) 1.43
Crystals of phosphorylcholine-binding Fab-fragments from mouse myeloma proteins: preparation and x-ray analysis. Proc Natl Acad Sci U S A (1972) 1.34
Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal. J Biol Chem (1985) 1.22
Structural basis for the specificity of antibody-antigen reactions and structural mechanisms for the diversification of antigen-binding specificities. Q Rev Biophys (1977) 1.19
H-2Dd exploits a four residue peptide binding motif. J Exp Med (1993) 1.13
Refined crystal structure of deoxyhemoglobin S. I. Restrained least-squares refinement at 3.0-A resolution. J Biol Chem (1985) 1.12
A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses (1997) 1.10
The structural and genetic basis for expression of normal and latent VHa allotypes of the rabbit. Mol Immunol (1984) 1.10
Variability of three-dimensional structure in immunoglobulins. Proc Natl Acad Sci U S A (1975) 1.09
On the specificity of antibody/antigen interactions: phosphocholine binding to McPC603 and the correlation of three-dimensional structure and sequence data. Ann Inst Pasteur Immunol (1985) 1.08
Structure-function analysis of a lupus anti-DNA autoantibody: central role of the heavy chain complementarity-determining region 3 Arg in binding of double- and single-stranded DNA. Eur J Immunol (2000) 1.06
Three-dimensional structure of hemoglobin from the polychaete annelid, Glycera dibranchiata, at 2.5 A resolution. J Biol Chem (1974) 1.05
An em study of phosphorylcholine-binding fab immunoglobulin fragment crystals. J Ultrastruct Res (1975) 0.98
Crystalline monoclonal antibody Fabs complexed to hen egg white lysozyme. J Mol Biol (1984) 0.98
Crystal structure of galactan-binding mouse immunoglobulin J539 Fab at 4.5-A resolution. Proc Natl Acad Sci U S A (1979) 0.89
Structural studies of human autoantibodies. Crystal structure of a thyroid peroxidase autoantibody Fab. J Biol Chem (1996) 0.88
Immunoglobulin structures at high resolution. Contemp Top Mol Immunol (1975) 0.88
A monoclonal anti-IgE antibody against an epitope (amino acids 367-376) in the CH3 domain inhibits IgE binding to the low affinity IgE receptor (CD23). J Immunol (1988) 0.87
Structural and genetic basis of idiotypy in the galactan-binding myeloma proteins. Ann Immunol (Paris) (1979) 0.87
Structures of complexes of rhizopuspepsin with pepstatin and other statine-containing inhibitors. Proteins (1992) 0.87
Binding characteristics of IgA 16.4.12E, a monoclonal antibody with specificity for the nonreducing terminal epitope of alpha-(1----6)-dextrans. Comparisons between IgA hybridoma 16.4.12E and myeloma W3129. J Biol Chem (1990) 0.87
Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Mol Immunol (1999) 0.86
Evolutionary and structural influences on light chain constant (CL) region of human and mouse immunoglobulins. Proc Natl Acad Sci U S A (1975) 0.86
A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int Immunopharmacol (2001) 0.85
Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. EXS (1995) 0.85
A humanized antibody with specificity for hepatitis B surface antigen. Hum Antibodies Hybridomas (1996) 0.84
Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma (1995) 0.84
Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E. Biochemistry (1998) 0.83
Evaluation of the structural variation among light chain variable domains. Mol Immunol (1979) 0.83
Twisting into shape. Curr Biol (1992) 0.83
Modeling of antibody combining sites. Methods Enzymol (1991) 0.82
A model of the Fc of immunoglobulin E. Mol Immunol (1986) 0.80
Identification of the high affinity receptor binding region in human immunoglobulin E. J Biol Chem (1996) 0.80
A T cell receptor V alpha domain expressed in bacteria: does it dimerize in solution? J Exp Med (1996) 0.80
A crystallographic study of deoxy cobalt (II) mesoporphyrin IX myoglobin. J Biol Chem (1975) 0.80
Crystalline semisynthetic ribonuclease-S'. Proc Natl Acad Sci U S A (1976) 0.79
Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. Clin Cancer Res (1999) 0.79
CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol (2000) 0.79
Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Crit Rev Oncol Hematol (2001) 0.79
Glycera dibranchiata hemoglobin. X-ray structure of carbonmonoxide hemoglobin at 1.5 A resolution. J Mol Biol (1994) 0.78
The nature and importance of the inter-epsilon chain disulfide bonds in human IgE. Eur J Immunol (1991) 0.78
Localization of rabbit kappa light chain allotypic determinants. Mol Immunol (1986) 0.78
Structural significance of sequence variability in antibody complementarity-determining regions. Res Immunol (1994) 0.77
Quantitation of the immunogenic potential of protein antigens. Mol Immunol (1985) 0.77
The X-ray crystal structure of a Valpha2.6Jalpha38 mouse T cell receptor domain at 2.5 A resolution: alternate modes of dimerization and crystal packing. J Mol Biol (1999) 0.77
Structure of the haemoglobin of the marine annelid worm, Glycera dibranchiata, at 5.5 A resolution. Nature (1968) 0.77
Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab'. Proteins (1993) 0.77
Two Ig framework I epitopic specificities recognized by a rabbit antiserum and a monoclonal antibody to mouse VH chains. J Immunol (1990) 0.77
Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38. Proc Natl Acad Sci U S A (1994) 0.76
Binding of modified fragments of the Shigella dysenteriae type 1 O-specific polysaccharide to monoclonal IgM 3707 E9 and docking of the immunodeterminant to its modeled Fv. Carbohydr Res (1998) 0.76
The codon for the methionine at position 129 (M129) in the human prion protein provides an alternative initiation site for translation and renders individuals homozygous for M129 more susceptible to prion disease. Med Hypotheses (2005) 0.76
Structure-function studies of anti-3-fucosyllactosamine (Le(x)) and galactosylgloboside antibodies. J Immunol (1994) 0.76
Structure-function studies of an anti-asialo GM1 antibody obtained from a phage display library. J Neuroimmunol (1999) 0.76
Why don't humans get scrapie from eating sheep? A possible explanation based on secondary structure predictions. Med Hypotheses (2005) 0.76
Peptide blocking of IgE/receptor interaction: possibilities and pitfalls. Allergy (1997) 0.75
Commerce versus collaboration. Lancet (1991) 0.75
Molecular-replacement structure determination of two different antibody:antigen complexes. Acta Crystallogr B (1990) 0.75
The structures of lamprey and bloodworm hemoglobins in relation to their evolution and function. Cold Spring Harb Symp Quant Biol (1972) 0.75
Are humans getting 'mad-cow disease' from eating beef, or something else? Med Hypotheses (2003) 0.75
Humanization of KC4G3, an anti-human carcinoma antibody. Hybridoma (1994) 0.75
Does mRNA translation starting from an alternative initiation site contribute to the pathology of Huntington's disease? Med Hypotheses (2000) 0.75
Antibody Fab assembly: the interface residues between CH1 and CL. Mol Immunol (1986) 0.75
Development of more efficacious antibodies for medical therapy and diagnosis. Prog Nucleic Acid Res Mol Biol (1998) 0.75
Structure/function studies on IgE as a basis for the development of rational IgE antagonists. Allergy (1998) 0.75
Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3. Adv Exp Med Biol (1994) 0.75
Protein and cell engineering of components of the human immunoglobulin E receptor/effector system: applications for therapy and diagnosis. Technol Health Care (1998) 0.75
Protein engineering from plants to animals, from big to small, from outside to inside and other advances. Curr Opin Biotechnol (1997) 0.75
Structure of a phosphorycholine-binding mouse myeloma Fab. Transplant Proc (1975) 0.75